La vendita allo scoperto per Molecular Data dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Molecular Data. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Molecular Data (OTC:MKDTY) Azioni, Report sulle vendite allo scoperto

Molecular Data Inc is a chemical e-commerce platform in China. It provides SaaS-powered and data-driven integrated service platform for chemical e-commerce. The company offers e-commerce solutions, financial solutions, and warehousing and logistics solutions through its platform. The company generates all its revenues through Chemical trading from China. It sells chemical products to customers through an online platform or sales representatives.

MOLECULAR DATA INC S/ADR by Molecular Data Inc.

Molecular Data Inc

WIIM

TLSA

Tiziana Life Sciences shares are trading higher after the company announced results from an open-label clinical study evaluating nasal foralumab.

Pasithea Therapeutics, Corp. ("Pasithea," or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>, KTTAW))), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced the pricing of a public offering of 3,571,428 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and accompanying Series C warrants to purchase up to 3,571,428 shares of common stock and Series D warrants to purchase up to 3,571,428 shares of common stock, at a combined offering price of $1.40 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants.
The Series C common warrants will have an exercise price of $1.40 per share and will be exercisable upon issuance and will expire five years thereafter. The Series D common warrants will have an exercise price of $1.40 per share and will be exercisable upon issuance and will expire 18 months thereafter. The closing of the offering is expected to occur on or about May 7, 2025, subject to the satisfaction of customary closing conditions.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.

News

Offerings

KTTA

Pasithea Therapeutics Announces Pricing Of $5M Public Offering Of 3,571,428 Shares Of Common Stock And Accompanying Series C Warrants To Purchase Up To 3,571,428 Shares Of Common Stock And Series D Warrants To Purchase Up To 3,571,428 Shares Of Common Stock, At A Combined Offering Price Of $1.40

PLOW

Douglas Dynamics shares are trading higher after the company reported better-than-expected Q1 financial results.

A previously overlooked stake once tied to the collapsed crypto exchange FTX may now be worth roughly $500 million, following a sharp rise in valuation at one of <a href="https://www.benzinga.com/money/how-to-invest-in-ai-startups">Silicon Valley's hottest AI startups</a>.
What Happened: Anysphere, the company behind the AI-powered code-writing assistant Cursor, has raised $900 million in new funding, tripling its valuation to $9 billion, Financial Times <a href="https://www.ft.com/content/a7b34d53-a844-4e69-a55c-b9dee9a97dd2">reported</a>.
This surge comes just months after FTX creditors offloaded their equity interest in Anysphere for only $200,000, according to a person familiar with the matter.
The massive valuation jump underlines just how costly distressed asset sales can be — and how rapidly AI start-ups are inflating in value. 
The new round was led by Thrive Capital, a backer of OpenAI, with participation from Andreessen Horowitz and Accel, according to people close to the deal.
Founded in 2022 by MIT alumni, Anysphere was last valued at $2.5 billion in January, when it raised $105 million from many of the same investors. 
Its flagship product, Cursor, has become popular with software engineers for enabling natural language-based coding and suggesting near-complete code blocks, often replacing manual development work.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45222346/florida-presses-pause-on-bitcoin-reserve-bill-heres-what-happened">Florida Presses Pause On Bitcoin Reserve Bill: Here&#8217;s What Happened</a>
The company reportedly reached $200 million in annual recurring revenue by April, making it one of the fastest-growing software firms in the space. 
Cursor is already used by developers at major tech companies including OpenAI, Stripe and Spotify.
Anysphere's rise comes amid broader investor enthusiasm for AI application developers, who are attracting attention now that valuations for foundational model builders like OpenAI and Anthropic have soared beyond the reach of most investors. 
According to Dealroom.co, AI application start-ups attracted $8.2 billion in funding in 2024, more than double the previous year.
What&#8217;s Next: The dramatic revaluation of Anysphere also spotlights a growing concern among some venture capitalists: that rapid revenue growth may stem more from short-term AI experimentation than from long-term, durable enterprise adoption.
Cursor, which Anysphere claims powers close to a billion lines of code daily, competes with offerings such as GitHub Copilot and has gained attention from high-profile technologists like Andrej Karpathy, who described using Cursor as entering a "vibe coding" trance.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45219180/etoro-eyes-5b-valuation-in-nasdaq-ipo-sets-price-range-at-4650-per-share">eToro Eyes $5B Valuation In Nasdaq IPO, Sets Price Range At $46–$50 Per Share</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

FTX Creditors Sold Potential $500M Anysphere Stake For $200,000 Before Startup's Valuation Tripled

C3.ai Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) shares fell 2% to $21.55 on Tuesday following Palantir Technologies Inc&#8217;s first-quarter <a href="https://www.benzinga.com/news/earnings/25/05/45208000/palantir-q1-earnings-revenue-beat-eps-in-line-customer-count-up-39-company-raises-guidance-citing-surging-and-ferocious-growth">earnings</a> release, which triggered a 14.3% decline in Palantir's stock despite strong performance metrics. 
Investors appear to be reassessing valuations across AI-focused software companies, including C3.ai, amid heightened expectations and aggressive growth guidance from larger peers like Palantir.
What To Know: C3.ai, a software company specializing in enterprise AI applications, faces investor scrutiny as Palantir continues to dominate the AI-driven enterprise software space. 
While Palantir <a href="https://www.benzinga.com/news/earnings/25/05/45208000/palantir-q1-earnings-revenue-beat-eps-in-line-customer-count-up-39-company-raises-guidance-citing-surging-and-ferocious-growth">beat revenue estimates</a> and raised its full-year guidance, its steep selloff suggests that even outperforming companies in the AI sector are vulnerable to high valuation concerns and pressure to sustain rapid growth.
Palantir's strong U.S. commercial revenue growth of 71% and robust deal flow underscore rising competition in AI software adoption. 
As a smaller player in the space, C3.ai may be struggling to justify its own growth prospects in comparison, prompting a modest stock decline as markets digest the implications of Palantir's dominant market position and forward-looking outlook.
Read Also: <a href="https://www.benzinga.com/25/05/45213810/palantir-stock-drops-925-after-earnings-beat-dan-ives-stays-bullish-but-jefferies-brent-thill-says-institutions-still-arent-interested">Palantir Is A &#8216;Retail-Driven Story,&#8217; Says Top Analyst As PLTR Stock Falls 9% In After-Hours: &#8216;Not A Single Institutional Investor&#8230;Talks About This&#8217;</a>
<h2 class="wp-block-heading">How To Buy AI Stock</h2>
By now you're likely curious about how to participate in the market for C3.ai &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of C3.ai, which is trading at $21.38 as of publishing time, $100 would buy you 4.68 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AI has a 52-week high of $45.08 and a 52-week low of $17.03.

C3.ai Stock Dips Following Palantir Technologies Earnings: What's Going On?

RLAY

Relay Therapeutics shares are trading lower following Q1 reported financial results.

BEAM

Beam Therapeutics shares are trading lower following a Q1 EPS and revenue miss.

UNIT

Uniti Group shares are trading lower after the company reported worse-than-expected Q1 sales results and cut its FY25 FFO guidance.

AVNS

Avanos Medical shares are trading higher after the company reported better-than-expected Q1 financial results.

<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/06090719/Newborn-Town.jpeg" alt="" class="wp-image-12372" style="width:920px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/06090719/Newborn-Town.jpeg 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/06090719/Newborn-Town-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/06090719/Newborn-Town-768x512.jpeg 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The Middle East-focused social media operator performed strongly in the first quarter, as its stock has been on a recent roll
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>Newborn Town's social networking revenue rose 40% year-on-year in the first quarter</li>
<li>Cumulative downloads of its social networking apps jumped 26% in the quarter from a year earlier</li>
</ul>
The tsunami unleashed by U.S. President Donald Trump's trade war has hammered global stock markets, including Hong Kong, whose benchmark Hang Seng Index plummeted last month as Chinese stocks took a bath. But as most tickers got pummeled,&nbsp;Newborn Town Inc.&nbsp;(9911.HK), sometimes called the "Tinder of the Middle East,' not only avoided the bloodbath, but saw its stock surge to new highs.
Newborn Town may not be a household name to ordinary Hong Kongers, but its social media apps are all the rage in the Middle East and North Africa (MENA). Those include names like its MICO platform for livestreaming, YoHo for audio social networking, TopTop for gamers and SUGO for lonely hearts in search of companionship. Most recently it rolled out its HeeSay social media app for the LGBTQ community last year.
The company's geographic focus makes it well positioned to withstand the raging trade war, reflected in its recently announced&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0424/2025042400399.pdf">first-quarter update</a>&nbsp;that showed a company with strong momentum. Cumulative downloads of its social networking apps totaled about 820 million by the end of the quarter, up 26% year-on-year, as it logged 32.84 million average monthly users during the period, up 15% from a year earlier.
Revenue from its social networking business reached between 1.35 billion yuan ($185 million) and 1.4 billion yuan during the quarter, up as much as 44% year-on-year. Its innovative businesses did even better, growing up to 88% year-on-year to between 155 million yuan and 175 million yuan, albeit off a much smaller base.&nbsp;
Newborn Town's stock rallied 5.1% after the quarterly update's release. The shares have doubled since the start of the year, easily beating the broader market. They held up even after Donald Trump's trade war began in early April, and rose 39% for the month.
<h4 class="wp-block-heading">Trade war safe haven</h4>
The company has a number of factors going for it during the global trade war originating in the U.S. For starters, many investors may believe its positioning in the social networking and gaming spaces makes it less vulnerable to the impact of rising tariffs. Geographically speaking, the company's focus on the MENA region is far from other places like China, Europe and Canada that are most in Donald Trump's crosshairs. Finally, the company has steered clear of the kinds of data security concerns plaguing TikTok and other Chinese companies with large amounts of offshore user data. All of those factors have allowed Newborn Town to stay above the fray despite its Chinese roots.
That status has lured investors, who are looking for such safe havens to park their funds as they flee more vulnerable stocks. The company's impressive performance and rising profits over the past few years have further underscored its relative resilience in the face of all the turbulence around it.
Newborn Town has been on a winning streak for most of the time since its IPO in 2019. Its one bad year, at least in terms of its bottom line, came in 2021 when it registered a loss of 390 million yuan. But even that was unrelated to its actual business and instead was the result of equity-based compensation expenses that rose by 651 million yuan.
The company logged profits of 130 million yuan and 510 million yuan in 2022 and 2023, respectively. The figure fell 6.3% to 480 million yuan last year, but even that was due to a high base the previous year when it recorded one-off gains from asset sales. Excluding those gains, its profit would have risen 30% last year.
<h4 class="wp-block-heading">Stock Connect candidate</h4>
The stock may also be getting a boost from its solid chances of being included in the Stock Connect program that makes Hong Kong-listed shares available to Mainland China-based buyers in Shanghai and Shenzhen. To be eligible for inclusion in the program, Hong Kong-listed companies must be component stocks in the Hang Seng, Hang Seng Composite MidCap or Hang Seng Composite SmallCap indexes, and have a market cap of at least HK$5 billion ($688 million).
Given its current size and market cap of more than HK$10 billion, along with high trading volume in its shares, the company could quite possibly be included in the Hang Seng Composite SmallCap Index first. From there it could be admitted into the Stock Connect program, which could further boost its shares as Shanghai- and Shenzhen-based investors pile in.
Second growth curve
Newborn Town is also on the prowl for its next big growth engine, which it thinks it may have found in the development of high-quality games. It earned 460 million yuan from such games last year, up 21.3% from 2023. The company says that quality is a top priority in its gaming business, and it pursues a strategy of developing evergreen games that generate good user experience and have long life cycles. Its "Alice's Dream: Merge Games" has made it onto Sensor Tower's list of top 30 Chinese mobile for overseas markets several times.
Its base now established in the Middle East, the company is also eying the more competitive European and Japanese markets. Senior vice president and senior company secretary Song Mingliang has told media Newborn Town is on the hunt for M&amp;A opportunities in those two markets to keep its revenue growing at a steady clip. He stressed that existing mobile internet operators in those markets have failed to provide users with more emotional value so far, leaving an opening for the likes of Newborn Town.
The company's booming shares may have delighted investors, but the rally has also raised the very real risk of a correction. The stock now trades a relatively frothy price-to-earnings (P/E) ratio of 22 times, which is well ahead of global leader&nbsp;Match Group's&nbsp;(MTCH.US) 15 times and more than double the 9.5 for the similar-sized&nbsp;Yalla&nbsp;(YALA.US), which also focuses on the MENA region. At such elevated levels, investors might want to exercise extra caution before jumping on to Newborn Town's strong growth story.

Asia

Equities

Opinion

Trading Ideas

General

This Stock Didn't Just Survive The Tariff Shakeup, It's Thriving

Barrington Research analyst Patrick Sholl maintains Marcus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCS#NYSE">MCS</a>) with a Outperform and maintains $25 price target.

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on Marcus, Maintains $25 Price Target

CGAU

Centerra Gold shares are trading higher after the company reported better-than-expected Q1 financial results.

VMEO

Vimeo shares are trading lower following Q1 reported financial results.

AESI

Atlas Energy Solutions shares are trading lower following a Q1 EPS miss.

AORT

Artivion shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance.

Tigress Financial analyst Ivan Feinseth maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $290 to $305.

AMZN

Tigress Financial Maintains Buy on Amazon.com, Raises Price Target to $305

Tidewater shares are trading higher following a Q1 EPS and revenue beat.

Ethan Allen Interiors shares are trading lower after the company reported worse-than-expected Q3 financial results. Also, Telsey Advisory Group cut its price target on the stock from $32 to $30.

Shares of Hyperscale Data Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#NASDAQ">GPUS</a>) soared over <a href="https://www.benzinga.com/25/05/45202027/hyperscale-data-stock-soars-on-preliminary-q1-and-fy25-guidance">400% on Monday</a> after the company reported preliminary financial results for first-quarter 2025, with revenue surpassing $25 million. On Tuesday, the stock retreated 24% to $5.88, likely on profit-taking.
What To Know: The company also <a href="https://www.benzinga.com/pressreleases/25/05/g45189872/hyperscale-data-announces-preliminary-25-million-in-revenue-for-q1-2025-provides-full-year-guidanc">issued</a> bullish full-year guidance, projecting revenue between $115 million and $125 million, citing year-over-year growth across subsidiaries including Ault Global Real Estate Equities, Circle 8 Crane Services and TurnOnGreen.
A key driver of first-quarter performance was a one-time $9.7 million gain tied to the deconsolidation of Avalanche International. In a strategic move, Hyperscale is also converting its Michigan data center into a next-generation AI facility, aiming to capture growth in the booming AI infrastructure sector.
CEO William B. Horne emphasized the company's focus on high-growth areas and streamlining operations via non-core asset divestitures.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45220645/us-trade-deficit-soars-to-record-140b-as-imports-rocket-ahead-of-trumps-tariffs">US Trade Deficit Soars To Record $140B As Imports Rocket Ahead Of Trump&#8217;s Tariffs</a>
<h2 class="wp-block-heading">How To Buy GPUS Stock</h2>
By now you're likely curious about how to participate in the market for Hyperscale Data &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Hyperscale Data, which is trading at $4.94 as of publishing time, $100 would buy you 20.24 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, GPUS has a 52-week high of $20.26 and a 52-week low of $1.23.

GPUS

Hyperscale Data (GPUS) Stock Falls After 400% Rally: What's Going On?

Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-07. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Amphastar Pharma will report an earnings per share (EPS) of $0.69.
Investors in Amphastar Pharma are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
The company's EPS missed by $0.02 in the last quarter, leading to a 9.72% drop in the share price on the following day.
Here's a look at Amphastar Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.94</td>
<td>0.99</td>
<td>0.77</td>
<td>0.74</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.92</td>
<td>0.96</td>
<td>0.94</td>
<td>1.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-10.0%</td>
<td>-14.000000000000002%</td>
<td>13.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746543855_0.png" alt="eps graph" />
<h3>Amphastar Pharma Share Price Analysis</h3>
Shares of Amphastar Pharma were trading at $25.12 as of May 05. Over the last 52-week period, shares are down 41.47%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Observations about Amphastar Pharma</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Amphastar Pharma.
Analysts have given Amphastar Pharma a total of 1 ratings, with the consensus rating being Neutral. The average one-year price target is $32.0, indicating a potential 27.39% upside.
<h3>Peer Ratings Overview</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Innoviva, Pacira BioSciences and Ocular Therapeutix, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Innoviva, with an average 1-year price target of $55.0, suggesting a potential 118.95% upside.</li>
<li>Analysts currently favor an Buy trajectory for Pacira BioSciences, with an average 1-year price target of $44.6, suggesting a potential 77.55% upside.</li>
<li>Analysts currently favor an Buy trajectory for Ocular Therapeutix, with an average 1-year price target of $15.83, suggesting a potential 36.98% downside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary outlines pivotal metrics for Innoviva, Pacira BioSciences and Ocular Therapeutix, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphastar Pharma</td>
<td>Neutral</td>
<td>4.73%</td>
<td>$86.65M</td>
<td>5.20%</td>
</tr>
<tr>
<td>Innoviva</td>
<td>Outperform</td>
<td>6.95%</td>
<td>$84.64M</td>
<td>2.99%</td>
</tr>
<tr>
<td>Pacira BioSciences</td>
<td>Buy</td>
<td>3.32%</td>
<td>$147.37M</td>
<td>2.10%</td>
</tr>
<tr>
<td>Ocular Therapeutix</td>
<td>Buy</td>
<td>15.41%</td>
<td>$15.85M</td>
<td>-14.50%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Amphastar Pharma ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, it is at the top. The consensus rating for Amphastar Pharma is Neutral.
<h3>Delving into Amphastar Pharma's Background</h3>
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
<h3>Understanding the Numbers: Amphastar Pharma's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Amphastar Pharma's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 4.73%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Amphastar Pharma's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 20.35% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Amphastar Pharma's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.2%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.43%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.89, Amphastar Pharma adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/AMPH/earnings">To track all earnings releases for Amphastar Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

AMPH

Earnings Outlook For Amphastar Pharma

Molecular Data

Comments

Molecular Data

Vendite allo scoperto

Molecular Data (OTC:MKDTY) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO